期刊
INTERNATIONAL JOURNAL OF CARDIOLOGY
卷 349, 期 -, 页码 134-137出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijcard.2021.11.059
关键词
Cardiotoxicity; Cardio-oncology; Breast Cancer; Cardiovascular prevention; Anthracyclines; Arterial hypertension
This study investigated the CV risk assessment, prescriptions of cardioactive drugs, and occurrence of CV events in breast cancer patients. The study found that patients with medium-to-high CV risk were more likely to receive cardioactive therapies, but the risk categories were not associated with LVD occurrence.
Background: the European Society of Cardiology Heart Failure Association (HFA) together with the International Cardio-Oncology Society (ICOS) proposed charts for baseline CV risk assessment of cancer patients scheduled to receive anthracyclines and anti-human epidermal growth factor receptor-2 (HER2) agents. Methods: We investigated HFA/ICOS risk stratification, prescriptions of cardioactive drugs, and occurrence of CV events in a multicentric breast cancer (BC) cohort from 3 Italian Outpatient Cardio-Oncology Clinics. Results: 373 BC patients who underwent a baseline Cardio-Oncologic evaluation were included, of whom 202 scheduled to receive anthracyclines and 171 anti-HER2. Mean age was 60 +/- 12 years and 49% of BC patients had >= 2 CV risk factors. In the anthracyclines group, 51% were at low-risk, 43% at medium-risk and 6% at high-risk; while in the anti-HER2 group, 27% patients were at low-risk, 58% at medium-risk and 15% at high-risk. In both groups, a medium-to-high risk was associated with use of cardioactive therapies (p < 0.0001). There were no LVD events in anthracycline recipients, and 16 LVD among anti-HER2 patients. A medium-to-high risk was not associated with LVD occurrence (p = 0.17). Conclusions: Patients with medium-to-high HFA/ICOS risk were more likely to receive cardioactive therapies, possibly explaining the lack of association of risk categories with LVD occurrence.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据